Gilead’s Yescarta and Novartis’ Kymriah garnered a lot of interest among T-cell therapies after producing high response rates in patients with lymphoma and leukemia. However, the same has not been true for this technology in cases of solid tumors. In this novel procedure, patients’ immune-boosting T cells are extracted and engineered to target and destroy cancer cells.
Updated clinical data on its T-cell therapies has been presented by Adaptimmune. The GlaxoSmithKline-partnered NY-ESO SPEAR T-cells have been linked by the latest readouts to a 50% partial response rate in heavily pretreated cancer patients and have led to the positioning of Adaptimmune for dialing up of dosing of two wholly owned assets.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.